BI-1607
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BI-1607, covering 2024-12-16 to 2025-11-19. Get the full timeline:
Most recent: Clinical Trial Update: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]